[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-369692-105":59,"doc-detail-369692-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","common-inherited-loss-of-function-mutations-in-the-innate-sensor-nod2-contribute-to-exceptional-immune-response-to-cancer-immunotherapy","Common inherited loss-of-function mutations in the innate sensor NOD2 contribute to exceptional immune response to cancer immunotherapy","","Investigating why cancer immunotherapy benefits only a subset of patients, this study tests whether inherited immune-tolerance checkpoint differences drive exceptional responses. Whole-genome sequencing identified biallelic germline NOD2 loss-of-function variants in exceptional responders and found their enrichment in anti-PD1 cohorts beyond population frequency. Gain-of-function RIPK2 alleles were enriched among nonresponders. Across recruited and independent cohorts, NOD2 loss-of-function associated with improved survival and response, and mouse validation confirmed enhanced anti-PD1 tumor immunity.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/common-inherited-loss-of-function-mutations-in-the-innate-sensor-nod2-contribute-to-exceptional-immune-response-to-cancer-immunotherapy/369692/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/common-inherited-loss-of-function-mutations-in-the-innate-sensor-nod2-contribute-to-exceptional-immune-response-to-cancer-immunotherapy/369692.png","ImageObject",300,407,{"name":92,"@type":93},"Cart","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-06","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",13,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"What genetic factor does the study focus on for exceptional responses to cancer immunotherapy?","Question",{"text":113,"@type":114},"The study focuses on inherited loss-of-function mutations in the innate immune sensor NOD2 and their role as an immune tolerance checkpoint affecting responses to checkpoint inhibition.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"How does NOD2 status relate to outcomes in anti-PD1 treatment cohorts?",{"text":118,"@type":114},"In anti-PD1 monotherapy cohorts, inherited NOD2 loss-of-function variants were enriched in exceptional responders and associated with improved overall survival and complete or partial response, with stronger effects in the presence of immune-related adverse events.",{"name":120,"@type":111,"acceptedAnswer":121},"What experimental evidence supports the clinical associations?",{"text":122,"@type":114},"Mouse experiments showed that germline Nod2 loss-of-function enhanced therapeutic immune responses induced by anti-PD1 monotherapy, increasing tumor infiltration by effector memory CD8 T cells.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},369692,1790829201,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":140,"language":141,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":67,"update_tm":145,"read_time":41,"preview_page_count":19,"preview_urls":146},18829141979164,"https://eur-avatar.wpscdn.com/davatar_6f874abed73319feea01a86fa6f0fab8","RESEARCH ARTICLE  \nIMMUNOLOGY AND INFLAMMATION  \n OPEN ACCESS  \nCommon inherited loss-of-function mutations in the innate sensor NOD2 contribute to exceptional immune response to cancer immunotherapy  \nMegan B. Barneta, b,c,d,1,2, Katherine J. L. Jacksona,1, Etienne Masle-Farquhara, Amanda Russella, Deborah L. Burnetta,e, Adrian Chyea, b,c, Chris J. Jaraa, b, Megan Faulksa, Amanda Mawsona, Timothy J. Petersa, Robert Brinka, b, Katherine Wrightc, India Allena, Simon Junankara, b, Ian D. Davisf,g, h, Gillian Helleri, Zia Khanj, Jeffrey Brucek, Cindy Yangk, Stephenie Prokopeck, Trevor Pughk, Andreas Behreng, l, m, Georgina L. Holdn, Fan Zhangn, Wendy A. Coopero, p,q, Bo Gaor,s, Adnan Nagrialp, r,s, Anthony M. Joshuaa, b,c, Thomas Johnt, Geoffrey Petersu, Rina Huiv, Michael Boyerp,w, Prunella L. Blinmanp,x, Steven C. Kaop,w,  \nJonathan Cebong, l, m,1, and Christopher C. Goodnowa, b,e,1,2 Affiliations are included on p. 11.  \nContributed by Christopher C. Goodnow; received August 18, 2023; accepted May 21, 2025; reviewed by Tasuku Honjo and Alan J. Korman  \nLung cancers and melanomas have many somatically mutated self-proteins that would be expected to trigger an immune rejection response, yet therapeutic responses can only be induced in a subset of patients. Here, we investigated the possibility that inherited differences in immune tolerance checkpoints contribute to variability in outcomes. Whole genome sequencing revealed biallelic germline loss-of-function (LOF) mutations in the immune tolerance checkpoint gene, NOD2, in an exceptional immune responder to targeted radiotherapy for metastatic melanoma. In 40 exceptional immune respondersto anti-PD1 monotherapy for non–small cell lung cancer (NSCLC), genome sequencing showed 30% had inherited a NOD2 LOF variant, more than twice the population frequency (P = 0.0021). Conversely, a gain-of-function RIPK2 allele known to increase NOD2 signaling was inherited by 61% of nonresponders from the same cohort, compared to 10% of exceptional responders and much higher than the population frequency (P \u003C 0.0001) . Within the overall recruited cohort of 144 NSCLC anti-PD1 patients, individuals with immune-related adverse events (irAE) had better overall survival, further improved in those with NOD2 LOF. In independent anti-PD1 monotherapy cohorts with a range of cancers, inherited NOD2 LOF was associated with complete or partial response (P = 0.0107) . Experimental validation in mice showed germline Nod2 LOF enhanced therapeutic immune responses elicited by anti-PD1 monotherapy against a high mutation burden colorectal cancer, increasing tumor infiltration by effector memory CD8 T cells. Collectively these results reveal common inherited human variation in an immune tolerance checkpoint is a determinant of cancer immune responses elicited by pharmacological inhibition of another checkpoint.  \ncancer immunotherapy | immune checkpoint inhibitor | immune-related adverse event | inherited variant | autoimmune disease  \nA cooperating series of immune tolerance checkpoints strikes a balance between mounting potent immune responses to pathogens and the need for tolerance to self-tissues and commensal microbes (1). Immunotherapy with monoclonal antibodies against PD-1 or CTLA-4 blocks one checkpoint to break tolerance to cancer cell neoantigens and self-antigens (2) . Nevertheless, even in tumors with a high mutational burden such as non–small cell lung cancer (NSCLC) in smokers, anti-PD1 checkpoint blockade provides a survival benefit in only a subset of patients, associated for some with induction of immune-related adverse events (irAEs) analogous to autoimmune diseases (3, 4) .  \nIn mouse genetic studies, breakdown of tolerance often requires a block in two or more checkpoints, illustrated by combined loss-of-function mutations in PD-1 and FAS (5), CBLB and AIRE (6), or PTPN6/SHP1, LYN, and CD22 (7) . Based on these observations, here we test the hypothesis that inherited checkpoint defects coopera","cbCaiccp6RiZRfbV","https://ap.wps.com/l/cbCaiccp6RiZRfbV","pdf",1212280,12,"English","# Results\n## Abscopal Cancer and Autoimmune Response to Radiotherapy in an Exceptional Melanoma Patient\n# Significance","[{\"question\":\"What genetic factor does the study focus on for exceptional responses to cancer immunotherapy?\",\"answer\":\"The study focuses on inherited loss-of-function mutations in the innate immune sensor NOD2 and their role as an immune tolerance checkpoint affecting responses to checkpoint inhibition.\"},{\"question\":\"How does NOD2 status relate to outcomes in anti-PD1 treatment cohorts?\",\"answer\":\"In anti-PD1 monotherapy cohorts, inherited NOD2 loss-of-function variants were enriched in exceptional responders and associated with improved overall survival and complete or partial response, with stronger effects in the presence of immune-related adverse events.\"},{\"question\":\"What experimental evidence supports the clinical associations?\",\"answer\":\"Mouse experiments showed that germline Nod2 loss-of-function enhanced therapeutic immune responses induced by anti-PD1 monotherapy, increasing tumor infiltration by effector memory CD8 T cells.\"}]","Common inherited loss-of-function mutations in the innate sensor NOD2 contribute to exceptional immune response to cancer immunotherapy | PDF",1790184113,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/6990c15146ec8286188353f2c5815f7f.webp",983,1316,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ee4af7ee44a608b72ba68515866b05cf.webp",982,1315,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e211d6de3708e79f038e82badd1935fe.webp",981,1313,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/7614a88504d204becfc8a9c546efbd18.webp",980,1312]